This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity or ...

Common semaglutide side effects include nausea, vomiting, diarrhea, and constipation. These should get better with time. Avoid fatty and greasy foods, and eat smaller meals to minimize ...

Simon Spichak finished his MSc at University College Cork, where he studied the interactions between the microbes in the gut and the brain. He became interested in science communication during his ...

Randomised trial data show GLP 1 receptor agonists are associated with increased risk of gallbladder and biliary disease, ...

Dramatic drops in the risk of cancer and heart problems have been associated with weight loss drugs, but so have digestive problems and blindness There has been meteoric demand for the weight loss ...

The Wegovy pill is expected to hit the market in January, joining injectable GLP-1 drugs that have transformed obesity treatment. One form you swallow, the other you inject. What else is different?

Research isn’t clear on whether semaglutide causes thyroid tumors. But people with a history of thyroid cancer may want to avoid using this diabetes and weight loss medication. Semaglutide is in a ...

A new study led by a researcher at University College London (UCL) suggests that the anti-obesity drug semaglutide may reduce the risk of heart attacks and other serious cardiac events even when ...

The FDA approved a pill version of the GLP-1 receptor agonist semaglutide (Wegovy), making it the first oral GLP-1 agent ...

Hospital trips tied to semaglutide—the active ingredient in Ozempic and Wegovy—are rare, but can be serious, a new study found Compounded versions of semaglutide could explain some of these visits, ...

The Food and Drug Administration has approved the first GLP-1 pill for weight loss and maintenance. Drugmaker Novo Nordisk ...